



**PRESS RELEASE**

*For Immediate Dissemination*

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

**OPSENS INC. PROVIDES ADDITIONAL DETAILS REGARDING ITS PROPOSED EQUITY FINANCING**

**QUEBEC CITY, Dec. 3, 2015 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Corporation") (TSXV:OPS) (OTCQX:OPSSF)** is pleased to announce it will file an amended and restated preliminary short form prospectus to provide additional details concerning its previously announced proposed marketed offering of units (the "Units"). The Company will offer up to 5,681,819 Units at a price of \$0.88 per Unit for gross proceeds of up to approximately \$5,000,000 (the "Offering"). The Offering will be conducted on a best efforts basis through Paradigm Capital Inc. ("Paradigm"), acting as lead agent, and including RBC Capital Markets and M Partners Inc. (collectively with Paradigm, the "Agents").

Each Unit consists of one common share in the capital of Opsens and one-half of one common share purchase warrant, each whole common share purchase warrant entitling the holder thereof to purchase one common share within 18 months from the closing date of the Offering at a price of \$1.20.

The Corporation has also agreed to grant the Agents an option to cover over-allotments and for market stabilization purposes (the "Over Allotment Option"), which will allow the Agents to arrange for purchasers to acquire up to 15% of the number of Units sold under the Offering. The Over Allotment Option will be exercisable, in whole or in part, at any time up to 30 days after the closing of the Offering.

The Corporation intends to use the net proceeds of the Offering to prepare the commercialization and marketing strategy of its Fractional Flow Reserve products, to fund research and product development and its working capital.

The Offering is being made pursuant to a short form prospectus filed in each of the provinces of Québec, Ontario, Alberta and British Columbia. A copy of the amended and restated preliminary short form prospectus will be available on SEDAR at [www.sedar.com](http://www.sedar.com).

The Offering is expected to close on or about December 22, 2015 and is subject to certain customary conditions and regulatory approvals, including the approval of the TSX Venture Exchange and the entering into by the Company and the Agents of an agency agreement.

This press release does not constitute an offer of securities for sale in the United States or to "U.S. persons" ("U.S. persons"), as such term is defined in Regulation S promulgated under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities being offered have not been, nor will be, registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from such registration requirements.

**About Opsens Inc. ([www.opsens.com](http://www.opsens.com) or [www.opsensmedical.com](http://www.opsensmedical.com))**

Opsens focuses mainly on the measure of Fractional Flow Reserve ("FFR") in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.

*Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

-30-

**For further information, please contact:**

Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996

Louis Laflamme, CPA, CA, Chief Executive Officer, 418.682.9996